U.S. Food and Drug Administration (FDA) Commissioner Marty Makary defended his leadership in a CNBC interview aired Tuesday, growing criticism with concerns centering on drug approval decisions and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Fintel reports that on October 20, 2025, JP Morgan upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underweight to Neutral. As of September 30, 2025, the average one-year price target ...

Shares of Replimune Group REPL soared 85.7% on Friday after the company announced that it had aligned with the FDA on the ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy ...